Beta Bionics, Inc. Common Stock

Day range

$19.08 – $20.54

Open

$19.08

Prev close

$19.16

Volume

504.16K

Market cap

$1.03B

Shares out

53.95M

P/E

—

P/S

8.68

P/B

4.03

P/FCF

—

ROE

-28.5%

ROA

-25.0%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Capital allocation updateSep 17, 2026

  We expect to use the net proceeds from this offering for general corporate purposes, which may include costs associated with the commercialization of Mint™, including expansion of our manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities and working capital and operating expenses.

• Regulatory decisionSep 15, 2026

  On September 14, 2026, we announced FDA clearance of Mint, our patch pump featuring a transformative reusable and disposable architecture ... for the treatment of T1D in adults and children six years of age and older.

• Annual meeting resultsMay 22, 2026

  On May 21, 2026, Beta Bionics, Inc. held its 2026 Annual Meeting of Stockholders. The Company's stockholders elected two Class I directors, Sean D. Carney and Christy Jones, to hold office until the 2029 Annual Meeting of Stockholders... The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

• Regulatory investigationJan 30, 2026

  On January 29, 2026, Beta Bionics, Inc. (the "Company") received a warning letter (the "Warning Letter") from the U.S. Food and Drug Administration (the "FDA") following inspection of the Company's facility in Irvine, California that occurred from June 9, 2025 through June 26, 2025. In the Warning Letter, the FDA cited deficiencies in the response letters sent by the Company to the FDA following the FDA's issuance of a Form 483, List of Investigational Observations.

• Preliminary resultsJan 8, 2026

  On January 8, 2026, Beta Bionics, Inc. (the "Company") issued a press release announcing its preliminary, unaudited fourth quarter 2025 topline financial results and key metrics.

Days to cover

3.3

Short interest

6.05M

Avg volume

1.86M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit
  negativeGlobeNewswire Inc.· Oct 26, 2026
• BBNX 9-DAY DEADLINE ALERT: Beta Bionics Facing Securities Class Action, Investors with Losses Encouraged to Contact Hagens Berman
  negativeGlobeNewswire Inc.· Oct 25, 2026
• ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Millrose Properties, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRP
  negativeGlobeNewswire Inc.· Oct 25, 2026
• Bronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
  negativeGlobeNewswire Inc.· Oct 25, 2026
• PZZA DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Papa John’s International, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - PZZA
  negativeGlobeNewswire Inc.· Oct 24, 2026